🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Windlas Biotech Limited WINDLAS NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://windlas.com

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.

READ MORE ›
₹833.10
-10.78% 1Y

Market & Price

Market Cap
₹1,719.20 Cr
Current Price
₹833.10
High / Low (52W)
₹1,070.80 / ₹705.75
Beta
0.31

Valuation

Stock P/E
26.74
Industry PE
37.60
Forward P/E
-
PEG Ratio
-
Book Value
₹254.44
Price to Book
3.27
P/S
1.90
EV/EBITDA
14.54
Dividend Yield
0.70%

Profitability & Returns

ROCE
15.65%
ROE
12.23%
ROA
5.55%
Profit Margin
7.35%
Op Margin
7.25%
EPS (Latest Qtr)
₹7.49
EPS (TTM)
₹31.16

Balance Sheet & Liquidity

Debt/Equity
0.06
Quick Ratio
1.55
Current Ratio
1.95
Debt
₹35.24 Cr
Total Assets
₹907.35 Cr
Current Assets
₹626.85 Cr
Working Capital
₹305.92 Cr

Ownership

Promoter Holding
67.41%
Chg in Prom Hold
-
FII / Inst Holding
8.75%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹1,523.40 Cr
Total Revenue (TTM)
₹904.09 Cr
EBITDA
₹104.74 Cr
Free Cash Flow
₹20.85 Cr
Operating Cash Flow
₹104.93 Cr
Shares Outstanding
₹2.06 Cr
Gross Margin
38.37%
Payout Ratio
18.62%

Growth (CAGR)

Revenue 5Y
20.98%
Profit 5Y
15.95%
Revenue (YoY)
17.70%
Earnings (YoY)
-2.60%

PROS

  • Compounding revenue at 21.0% over 5 years.
  • Profit CAGR of 16.0% over 5 years.
  • Generates positive free cash flow.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 WINDLAS Windlas Biotech Limited NSEPHARMA 833.10 26.74 ₹1,719.20 Cr 0.70% 15.65% 12.23% 20.98% 15.95%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -195.02 Cr202.71 Cr210.09 Cr222.40 Cr233.10 Cr238.50 Cr
Cost of Revenue -120.83 Cr125.19 Cr129.73 Cr136.95 Cr143.50 Cr147.05 Cr
Gross Profit -74.19 Cr77.51 Cr80.36 Cr85.45 Cr89.60 Cr91.45 Cr
Operating Expenses -56.50 Cr60.30 Cr61.28 Cr64.49 Cr72.92 Cr74.16 Cr
Operating Income -17.69 Cr17.21 Cr19.08 Cr20.96 Cr16.68 Cr17.29 Cr
EBITDA -28.74 Cr30.48 Cr31.76 Cr32.20 Cr28.95 Cr29.64 Cr
Interest Expense -1.46 Cr1.33 Cr1.06 Cr1.02 Cr1.28 Cr1.48 Cr
Pretax Income -20.34 Cr20.82 Cr23.26 Cr23.59 Cr19.97 Cr20.16 Cr
Tax Provision -4.76 Cr4.54 Cr5.59 Cr5.79 Cr4.97 Cr4.17 Cr
Net Income -15.58 Cr16.28 Cr17.66 Cr17.80 Cr15.00 Cr15.99 Cr
Diluted EPS 7.437.387.698.348.407.057.49

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -510.58 Cr628.88 Cr759.88 Cr904.09 Cr
Cost of Revenue -325.45 Cr396.18 Cr471.86 Cr557.23 Cr
Gross Profit -185.13 Cr232.71 Cr288.02 Cr346.86 Cr
Operating Expenses -137.21 Cr167.98 Cr221.90 Cr272.86 Cr
Operating Income -47.92 Cr64.73 Cr66.12 Cr74.00 Cr
EBITDA -70.19 Cr91.64 Cr112.12 Cr122.55 Cr
Interest Expense -78.80 L1.10 Cr4.38 Cr4.83 Cr
Pretax Income -57.04 Cr77.09 Cr79.76 Cr86.98 Cr
Tax Provision -14.41 Cr18.90 Cr18.76 Cr20.52 Cr
Net Income -42.63 Cr58.19 Cr60.99 Cr66.46 Cr
Diluted EPS 18.5819.7027.8828.80-

Compounded Sales Growth

5 Years:20.98%
1 Year:17.70%

Compounded Profit Growth

5 Years:15.95%
1 Year:-2.60%

Stock Price Performance

1 Year:-10.78%
6 Months:+4.92%
3 Months:+6.75%
1 Month:-2.62%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -528.98 Cr626.21 Cr760.45 Cr907.35 Cr
Current Assets -353.54 Cr431.29 Cr525.13 Cr626.85 Cr
Cash & Equivalents -3.69 Cr5.29 Cr42.40 L53.50 L
Inventory -74.74 Cr62.19 Cr81.38 Cr61.82 Cr
Receivables -116.86 Cr136.28 Cr166.86 Cr227.40 Cr
Total Liabilities -126.70 Cr176.27 Cr254.68 Cr326.51 Cr
Current Liabilities -121.24 Cr171.75 Cr249.44 Cr320.93 Cr
Long Term Debt 44.40 L10.90 L00-
Total Debt -4.99 Cr3.64 Cr32.60 Cr35.24 Cr
Total Equity -402.27 Cr449.94 Cr505.77 Cr580.84 Cr
Shares Outstanding -2.18 Cr2.08 Cr2.10 Cr2.11 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -60.97 Cr108.96 Cr68.19 Cr104.93 Cr
Investing Cash Flow --14.11 Cr-92.07 Cr-74.06 Cr-91.79 Cr
Financing Cash Flow --43.74 Cr-15.29 Cr1.01 Cr-13.03 Cr
Capital Expenditure --70.89 Cr-37.68 Cr-52.19 Cr-67.66 Cr
Free Cash Flow --9.93 Cr71.28 Cr15.99 Cr37.27 Cr
Net Change in Cash -3.12 Cr1.60 Cr-4.86 Cr11.10 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -36.3%37.0%37.9%38.4%
Operating Margin % -9.4%10.3%8.7%8.2%
Net Margin % -8.3%9.3%8.0%7.4%
ROE % -10.6%12.9%12.1%11.4%
ROCE % -11.8%14.2%12.9%12.6%

Shareholding Pattern

Insiders
67.41%
Institutions
8.75%
Public Float
26.84%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for WINDLAS

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space